Biden makes another push for cancer moonshot initiative
Sep 13, 2022
The president likened JFK’s space race to his own effort to slash cancer rates by 50% in the next 25 years.
Bipartisan group pushes CMS to expand coverage for Alzheimer’s treatments
By
Kimberly Bonvissuto
Feb 21, 2023
Access to federally approved monoclonal antibody and other disease-modifying therapies for Alzheimer’s disease will be “extremely limited” unless the Centers for Medicare & Medicaid Services reconsiders...
Alzheimer’s film: Not many surprises for you, but maybe some for general public
By
Lois A. Bowers
Jan 30, 2017
Those who care for residents with Alzheimer’s disease every day shouldn’t expect many surprises from a new PBS documentary, “Alzheimer’s: Every Minute Counts.” But you still...
Facility staff and families both struggle to figure out processes for dementia patients, report reveals
By
Kimberly Bonvissuto
Mar 20, 2024
It’s not just family caregivers who face challenges navigating dementia care — the nation’s healthcare workers also said they had difficulties providing care coordination through a complex healthcare...
Smartwatch tool predicts Parkinson’s disease up to 7 years before onset
By
Aaron Dorman
Jul 11, 2023
Data from a smart watch could help predict Parkinson’s disease up to seven years before symptoms begin occurring, a new study shows.
Memory care approach cuts antipsychotic med use in more than 50% of residents: study
By
Lois A. Bowers
Nov 18, 2019
A person-centered approach to memory care led to the reduced or discontinued use of off-label antipsychotic medications in more than half of the residents of 53 long-term care communities, including assisted...
Alzheimer’s Association asks CMS to provide full coverage of FDA-approved dementia drugs
By
Kimberly Bonvissuto
Dec 21, 2022
Every day, more than 2,000 older adults living with mild dementia may transition to a more advanced stage of the disease and no longer be eligible for lecanemab and other antibodies targeting amyloid under...
Alzheimer’s experts throw support behind experimental drug despite adverse events, deaths
By
Kimberly Bonvissuto
Dec 01, 2022
Alzheimer’s disease experts are throwing their support behind the drug lecanemab, despite reports of two deaths tied to the experimental monoclonal antibody medication.
How to scale memories, build community and enhance quality of life through 3-D stories
By
Douglas Cole
Mar 21, 2019
Preliminary results of studies on the effectiveness of 3-D presentations at senior living communities in the United States and Canada are promising.
AI could be therapeutic deejay for seniors with dementia, agitation
By
Aaron Dorman
Sep 19, 2023
A new AI-enabled tool can use wearable sensors and adaptive music systems to help older adults with dementia and agitation.